IMMX Immix Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873835 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-96.3%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-26.9%
ROA-25.3%
ROIC (approx.)-1,121.6%
Asset turnover—
Leverage & solvency
Liabilities / assets3.1%
Debt / equity0.00x
Current ratio33.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $16.26M | $11.29M | $8.74M | $4.20M | $126,527 |
| SG&A expense | $13.70M | $11.38M | $7.41M | $4.02M | $1.23M |
| Operating income | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -$1.35M |
| Interest expense | — | — | — | $497 | $179,853 |
| Pretax income | -$29.40M | -$21.66M | -$15.57M | -$8.22M | -$24.38M |
| Income tax | $37,724 | $41,037 | $26,415 | $10,268 | $6,013 |
| Net income | -$29.44M | -$21.61M | -$15.43M | -$8.23M | -$24.38M |
| EBITDA | -$29.71M | -$22.64M | -$16.14M | -$8.22M | -$1.35M |
| EPS (basic) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 |
| EPS (diluted) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 |
| Weighted avg. shares (diluted) | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M |
| Balance sheet | |||||
| Cash & equivalents | $93.93M | $17.68M | $17.51M | $13.44M | $17.64M |
| Short-term investments | $6.48M | — | — | — | — |
| Current assets | $101.24M | $20.20M | $19.79M | $14.90M | $18.19M |
| PP&E, net | $2.52M | $1.74M | $50,181 | $3,560 | $5,695 |
| Total assets | $104.84M | $22.95M | $19.93M | $14.91M | $18.19M |
| Current liabilities | $10.11M | $8.69M | $3.72M | $1.27M | $202,039 |
| Total liabilities | $11.04M | $9.70M | $3.72M | $1.75M | $202,039 |
| Shareholders' equity | $93.80M | $13.25M | $16.41M | $13.16M | $17.99M |
| Shares outstanding | 52.95M | 27.54M | 19.92M | 13.89M | 13.23M |
| Cash flow statement | |||||
| Operating cash flow | -$23.93M | -$14.60M | -$11.37M | -$7.41M | -$1.59M |
| Capital expenditure | $732,925 | $1.18M | $52,089 | — | $802 |
| Free cash flow | -$24.66M | -$15.77M | -$11.42M | — | -$1.59M |
| Investing cash flow | -$7.21M | -$1.18M | -$52,089 | — | -$802 |
| Financing cash flow | $107.39M | $15.95M | $15.46M | $3.23M | $18.85M |
| Depreciation & amortization | $245,747 | $32,941 | $5,468 | $2,135 | $2,468 |
| Stock-based compensation | $2.44M | $3.02M | $2.57M | $624,069 | $218,983 |
| Share buybacks | — | — | — | $99,963 | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.